Bristol-Myers Squibb's (BMS) device sales rise 13% in third quarter
This article was originally published in Clinica
Executive Summary
Bristol-Myers Squibb has seen a 13% increase in medical device sales in the third quarter. The company attributes this rise partly to the acquisition of Calgon Vestal Labs but also to continued growth in ostomy and woundcare products. The Nexgen knee replacement system, which was introduced in the first quarter, has experienced strong initial acceptance, says BMS.